BCMA特异性诱导多能干细胞分化为靶向多发性骨髓瘤的年轻化CD8αβ+ T细胞
本研究将异源肽BCMA72-80(YLMFLLRKI)特异性CD8+记忆细胞毒性T淋巴细胞通过表观遗传重编程为诱导多能干细胞,再分化为造血祖细胞及T细胞谱系,最终产物呈成熟CD8αβ+记忆表型、高表达CD38、CD28和41BB、不表达CTLA4、PD1、LAG3、TIM3及CD57,并对多发性骨髓瘤产生强增殖和多功能免疫应答。
要点
- BCMA特异性CD8+记忆CTL经表观遗传重编程为iPSC后可再分化为CD8αβ+记忆T细胞。
- 终产物高表达CD38、CD28和41BB,不表达CTLA4、PD1、LAG3、TIM3及CD57。
- BCMA特异性iPSC-T细胞具单一T细胞受体克隆型,对BCMA肽有特异性识别。
核心结论
- 本研究突显iPSC技术应用于过继性T细胞治疗方案的潜力,并识别可作为筛选合适iPSC克隆生物标志物的特定转录模式,以成功开发抗原特异性CD8αβ+记忆T细胞改善多发性骨髓瘤患者结局。
研究设计与样本
- 将异源肽BCMA72-80(YLMFLLRKI)特异性CD8+记忆细胞毒性T淋巴细胞表观遗传重编程为多能状态,发育为造血祖细胞(CD34+ CD43+/CD14- CD235a-),分化为T细胞谱系并评估其针对多发性骨髓瘤的多功能活性。
主要发现
- 终产物呈成熟CD8αβ+记忆表型,高表达CD38、CD28和41BB,不表达CTLA4、PD1、LAG3、TIM3及CD57。
- BCMA特异性iPSC-T细胞对多发性骨髓瘤表现出强增殖和多功能免疫应答。
- BCMA特异性iPSC-T细胞具单一T细胞受体克隆型,具同源BCMA肽识别和对多发性骨髓瘤靶向特异性。
- RNA测序分析显示所选iPSC克隆存在全基因组转录偏移和独特转录谱,可发育为CD8αβ+记忆T细胞。
- 该转录谱包括促进T细胞谱系发育、记忆CTL活化和免疫应答调控的基因调节因子(LCK、IL7R、4-1BB、TRAIL、GZMB、FOXF1和ITGA1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A major hurdle in adoptive T-cell therapy is cell exhaustion and failure to maintain antitumor responses. Here, we introduce an induced pluripotent stem cell (iPSC) strategy for reprogramming and revitalizing precursor exhausted B-cell maturation antigen (BCMA)-specific T cells to effectively target multiple myeloma (MM). Heteroclitic BCMA72-80 (YLMFLLRKI)-specific CD8+ memory cytotoxic T lymphocytes (CTL) were epigenetically reprogrammed to a pluripotent state, developed into hematopoietic progenitor cells (CD34+ CD43+/CD14- CD235a-), differentiated into the T-cell lineage and evaluated for their polyfunctional activities against MM. The final T-cell products demonstrated (1) mature CD8αβ+ memory phenotype, (2) high expression of activation or costimulatory molecules (CD38, CD28, and 41BB), (3) no expression of immune checkpoint and senescence markers (CTLA4, PD1, LAG3, and TIM3; CD57), and (4) robust proliferation and polyfunctional immune responses to MM. The BCMA-specific iPSC-T cells possessed a single T-cell receptor clonotype with cognate BCMA peptide recognition and specificity for targeting MM. RNA sequencing analyses revealed distinct genome-wide shifts and a distinctive transcriptional profile in selected iPSC clones, which can develop CD8αβ+ memory T cells. This includes a repertoire of gene regulators promoting T-cell lineage development, memory CTL activation, and immune response regulation (LCK, IL7R, 4-1BB, TRAIL, GZMB, FOXF1, and ITGA1). This study highlights the potential application of iPSC technology to an adaptive T-cell therapy protocol and identifies specific transcriptional patterns that could serve as a biomarker for selection of suitable iPSC clones for the successful development of antigen-specific CD8αβ+ memory T cells to improve the outcome in patients with MM.
引用
- Bae J, Kitayama S, Herbert Z, et al. Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma. Blood. 2024. PMID: 37890146. doi:10.1182/blood.2023020528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。